# Journal of Applied Pharmaceutical Science

ISSN: 2231-3354 Received on: 13-06-2012 Revised on: 04-08-2012 Accepted on: 16-08-2012 **DOI:** 10.7324/JAPS.2012.2812

N. Muninathan, C. Selvakumar, S. Malliga and J. Kumar Department of Biochemistry, Meenakshi Medical College and Research Institute, Enathur, kanchipuram, Tamilnadu-631552, India.

For Correspondence Dr. C. Selvakumar Assistant Professor, Department of Biochemistry, Meenakshi Medical College and Research Institute, Enathur, Kanchipuram, Tamilnadu-631552, India. Available online at www.japsonline.com

## Effect of Paclitaxel and Paclitaxel-Di Allyl Sulfide Combination on 7, 12 Dimethyl Benz (A) Anthracene (DMBA) Induced Skin Cancer in Wistar Rats: A Comparative Study

N. Muninathan, C. Selvakumar, S. Malliga and J. Kumar

#### ABSTRACT

Cancer is a cellular tumor that unlike benign tumor can metastasize and invade the surrounding tissues. In the present study the anticancer effect of paclitaxel was evaluated on 7, 12 Di Methyl Benz (a) Anthracene induced skin cancer in wistar rats and results were compared with normal, paclitaxel and paclitaxel-Di allyl sulfide combined alternative chemotherapy. By analyzing the various biochemical parameters (lipid Profile and lipid metabolizing enzymes) and Marker enzymes (squamous cell antigen). Skin cancer was induced in rats by 7, 12 Di methyl benz(a) anthracene (DMBA) at the dosage of 5 µg was dissolved in 100µl and administered into experimental animals for 28 weeks. In this study, we demonstrated that combination of paclitaxel and Di allyl sulfide protects the rats from a lethal dose of DMBA for 30 days. Total cholesterol (TC), free cholesterol (FC), phospholipids (PL) and triglycerides (TG) were found to be significantly increased whereas ester cholesterol (EC) and free fatty acids (FFA) were significantly decreased when compared with cancer bearing group II animals. From the present study, the effect of Paclitaxel- Di allyl sulfide combination proved to be a more significant chemotherapeutic agent against DMBA induced skin cancer in wistar rats compared to that of paclitaxel by analyzing the lipid profile and lipid metabolizing enzymes and marker enzymes.

Keywords: Skin cancer, 7, 12 Dimethyl benz (a) Anthracene (DMBA), Paclitaxel, Di allyl sulfide.

### INTRODUCTION

Cancer is a cellular tumor that unlike benign tumor, can metastasize and invade the surrounding tissues.. Cancer has been the major cause of death after cardio vascular disease. Humans of all ages develop cancer. Cancer is derived from Latin means "CRAB". Cancer is life threatening. Neoplasms are abnormal uncontrolled proliferation of cells. Neoplasms can be benign or malignant (Cancer). Cancer can be classified into three types. They are Sarcoma, Carcinoma and Lymphoma. Skin cancer is a type of Carcinoma. It is not a single disease. It is associated with oral cancer. Prevalence of skin cancer in Indian population is 1,460 members affected (Adams et al, 1991). Skin cancer has two most common forms of skin cancer - Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), which together account for over one million new cases each year (Arial et al, 2003).

Exposure to ultra violet radiation is the single most important risk factor in the etiology of skin cancer (A1.Dawood, 2000). Variations in the incidence of Cutaneous Malignant Melanoma (CMM) between similar populations living at similar latitudes suggest that other factors including diet may play a role (Arora and Shukla, 2002). Experimental studies on mice provide evidence that dietary fat in general and polyunsaturated fat in particular, may enhance the carcinogenic effects of ultra violet radiations (Bates, 1991 and Bates et al, 1987). Many patients seek out for alternative medicine after they have tried conventional medicine and found it to be ineffective or result in side effects (Black et al, 1992 and Henderson et al, 1991). The present work is executed to compare the anticancer effect of Paclitaxel and Paclitaxel - Di allyl sulfide combination on DMBA induced skin cancer in wistar rats. The serum and liver homogenate of the skin cancer rats were tested for lipid profile and lipid metabolizing enzymes. The results of the skin cancer induced rat were compared with controls for the study.

#### MATERIALS AND METHODS

#### Animals

Wistar rats (150 – 200 gms.) were purchased from Meenakshi medical college and Research Institute, Kanchipuram, India and were used throughout the study. They were maintained in controlled environmental conditions of temperature and humidity on alternative 12 hr light/dark cycles. All animals were fed standard pelleted diet (Gold Mohr rat feed, Ms.Hindustan lever Ltd. Mumbai) and water ad libitum. This research work on wistar rats was sanctioned and approved by the Institutional Animal Ethical Committee (REG NO. 765/03/ca/CPCSEA).

#### **Experimental protocol**

The animals were divided into six groups and each group consists of six animals.

Group I	:	Control animals
Group II	:	Acetone (100 $\mu$ L ) applied topically
		Followed 1hour later by DMBA (5 $\mu$ g ) per animal in Acetone (100 $\mu$ L ), three
		times a week for 28 weeks.
Group III	:	Skin cancer bearing animals treated
		with Paclitaxel (33mg/Kg.body weight)
		weekly once for four weeks.
Group IV	:	Skin cancer bearing animals treated
-		with DAS for 30 days. $(250\mu g/animal)$
Group V	:	Skin cancer bearing animals treated
*		with both paclitaxel and DAS for 30
		days.
Group VI	:	Control animals treated with paclitaxel
*		and DAS for 30 days.

At the end of experimental period the animals were sacrificed by cervical decapitation. Blood and tissues like skin and liver were collected. The tissues were immediately weighed and then homogenized in Tris HCl buffer 0.1 M (pH 7.4).

#### **Biochemical analysis**

Total cholesterol was estimated by the method of Perekh and Jung (1970). The free cholesterol was analyzed by Leffler and McDouugald (1963), Triglycerides and Free fatty acids by Rice (1970) and Hron (1981) respectively. Lipid metabolizing enzymes lipoprotein lipase and lecithin cholesterol acyl transferase by Schmidt (1974) and Legraud (1979) respectively.

#### STATISTICAL ANALYSIS


For statistical analysis, one way analysis of Variance (ANOVA) was used, followed by the Newman-Keuls Multiple Comparison test.

#### RESULTS

The fig 1 shows the effect of paclitaxel and Di allyl sulfide on lipid profile in the liver of control and experimental animals. Total cholesterol (TC), free cholesterol (FC), phospholipids (PL) and triglycerides (TG) were found to be significantly increased whereas ester cholesterol (EC) and free fatty acids (FFA) were significantly decreased when compared with cancer bearing group II animals. On Treatment with paclitaxel (G-III) lead to a significant decrease in the lipid profile and also a significant increase in the EC and FFA levels when compared with cancer induced animal (G- II). Di allyl sulfide (G-IV) also exhibited the same pattern of changes with a significant decrease in the overall lipid profile except EC and FFA, which was significantly increased after treatment. However the effect shown by the combined treatment of paclitaxel and Di allyl sulfide was more promising with significant decrease in the levels of TC, FC, PL, and TG along with a significant increase in EC and FFA levels when compared with the cancer-induced group. There was no significant difference in the lipid profile levels between the control animals (G-I) and the control treated with the combination of paclitaxel and Di allyl sulfide (G-VI).

The fig. 2 represents the effect of paclitaxel and Di allyl sulfide on lipid metabolizing enzymes in the liver of control and experimental animals. The activities of lipoprotein lipase (LPL) and lecithin cholesterol acyl transferase (LCAT) were found to be significantly decreased in cancer induced animals (G- II) when compared with control (G- I) animals. On treatment with paclitaxel (G-III) the activities of LPL and LCAT were significantly increased when compared with cancer induced group. Di allyl sulfide (G-IV) treatment also caused a significant increase in LPL and LCAT activities. However, combination treatment with both Di allyl sulfide and paclitaxel (G-V) caused a much significant increase in LPL and LCAT activities when compared with cancer bearing animals (G- II). There was no significant difference in the lipid metabolizing enzymes levels between the control animals (G-I) and the control treated with the combination of paclitaxel and Di allyl sulfide (G-VI).

Fig. 3 shows the activities of lipid metabolizing enzymes in plasma of control and experimental animals. Lipoprotein lipase (LPL) and lecithin cholesterol acyl transferase (LCAT) activities were found to be significantly decreased in the cancer induced animals (G-II) when compared with control (G- I) animals. Paclitaxel (G-III) treatment caused a significant increase in the activities of LPL and LCAT when compared with cancer-induced group. Di allyl sulfide treatment also caused a significant increase in LPL and LCAT activities. However, combination treatment with both Di allyl sulfide and paclitaxel (G-V) caused a much significant increase in LPL and LCAT activities when compared with cancer bearing animals (G- II). There was no significant difference in the enzyme activities in control animals (G-I) and the control animals treated with paclitaxel and Di allyl sulfide (G-VI).



Each value is expressed as mean <u>+</u>SD for six rat in each group a - as compared with Group I b - as compared with Group II Statistical signifance - \*p<0.001 @ p<0.01 #p<0.05, NS - Not significance




Fig. 1: Effect of paclitaxel along with Di allyl sulfide on lipid profile in the liver of control and experimental groups.

Fig. 2: Effect of paclitaxel along with Di allyl sulfide on lipid metabolizing enzymes in the liver of control and experimental animals.

Statistical signifance - \*p<0.001 @ p<0.01 #p<0.05, NS - Not significance




Fig. 3: Effect of paclitaxel along with Di allyl sulfide on the activities of lipid metabolising enzymes in plasma of control and experimental animals .

#### DISCUSSION

Cancer is associated with higher lipid metabolizing activity and cholesterol metabolism is regulated differently during tumor growth (Beck and Tisdale, 1981). Deregulated cholesterogenesis observed in tumors implicated an over production that could result in the enrichment of tumor cell membrane with cholesterol (Dessi et al., 1992). Abnormal levels of lipid profile and their changes in lipid metaboilising enzymes are proportionate to the disease stage. Elevated cholesterol level precedes the observed changes in DNA and protein content suggested a link between cholesterol and DNA synthesis pathway. In the present study it was observed the elevated levels of TC, FC and PL with a decrease in EC and FFA in cancer bearing (G-II) animals. Thirunavukkarasu et al., (2003), Diatlovitskaia and Bergelison (1982) have also reported the same. The decrease in the levels of EC and increase in FC levels in cancer bearing animals may be due to multiplication of already proliferating cells (Rao et al., 1986).

The progression and proliferation of the tumor cells depends on the elevation of cholesterol and PL levels which modifies the lipid fluidity of the tumor cell membranes thereby increasing the rate of malignancy in tumorous conditions (Damen *et al.*, 1984). Bergelson *et al.*, (1970) have reported that the activation of various carcinogenic factors leads to alterations in membrane synthesis accompanied by changes in PL components of tumor cell membrane. Several reports also revealed the changes in the distribution of TC in animals observed during progression of tumor growth (Dessi *et al.*, 1992). Ray *et al.*, (1997) and Potischman *et al.*, (1991) have observed significantly higher levels

of TG's in skin cancer patients when compared with controls. TG's are metabolized by LPL and the reaction products FFA and glycerol may then recirculated to the liver from which they readily cross the cell membrane (Dessi *et al.*, 1992).

LPL is the key enzyme responsible for the hydrolysis of TG's that are shown to be significantly reduced during tumor growth (Damen *et al.*, 1984). Hypertriglyceridemia in cancer bearing rats may be due to the clearance defect associated with lowered LPL activity. LPL have been observed in skin cancer bearing rats. This decrease in LPL activity may be due to HDL competing with the substrate for binding to the enzymes (Rogers and Hutchinron, 1981).

During hydrolysis of TG's core of chylomicrons and VLDL reductant surface constituent e.g., PL's and cholesterol are transferred to HDL when the cholesterol is esterified by LCAT (Helmes *et al.*, 1998). LCAT is the central enzyme responsible for the esertification of FC in various cells and tissues. The observed decrease in LCAT in cancer bearing animals may be due to the rapid multiplication of the already proliferating cells. This decrease in LCAT activity observed in skin cancer condition is responsible to maintain low EC level by reducing the efflux of FC from the proliferating cells and the influx of cholesteryl ester in to the cells (Bergelson *et al.*, 1970).

In paclitaxel and DAS treated animals the lipid profile and the lipid metabolizing enzymes were reduced to normal levels. A combination of paclitaxel and DAS is reported to positively affect the HDL and LDL levels of the rats (Kolanjiappan *et al.*, 2002). It has been shown to stimulate various enzyme systems, cell metabolism and circulation. Staveric and Matula (1992) have reported the effect of flavanoids in reducing TG level. The paclitaxel and DAS are powerful antioxidants and they have been shown to be capable of protecting against alterations in lipid metabolism.

#### CONCLUSION

From the present study, the effect of Paclitaxel- DAS combination proved to be a more significant chemotherapeutic agent against DMBA induced skin cancer in wistar rats compared to that of paclitaxel by analyzing the various biochemical parameters, lipid profile and lipid metabolizing enzymes.

#### REFERENCES

Adams, J. M and Cory, S. Transgenic models of tumor development science .Science, New series1991; 254: 1161 – 1167

A1- Dawood KM. Alternative medicine which may forward (Editorial) Journal of family and community medicine. 2000; 7:13 - 15

Arias E, Smith BL, (2003). Deaths: Preliminary data for 2006. Natl vital stat rep.2006; 51: 1-48

Arora, A. Shukla Y. Induction of apoptosis by DMBA induced Mouse \ skin tumor. Nutr cancer 2002; 44: 89 - 94

Bates, SE. Clinical application of serum tumors markers. Ann intern med. 1991; 115: 623-38.

Bates SE, Longo DL. Use of tumor markers in cancer diagnosis and management. Semin oncolo.1987; 14: 102 – 38

Beck SA and Tisdale MJ. Lipid mobilising factors specifically associated with cancer cachexia. Br. J. cancer 1981;63: 846-860.

Bergelson LD, Diatlovitskaia EV Torkhovskyaya TI, Sorokina LB and Gorkova NP. Phospholipid composition of membranes in the tumor cells. Biochim.Biophys. Act .1970; 210:287-298.

Black HS, Thornby J, Gergins J, Lenger L. Influence of dietary omega 6, 3 fatty acids source on the initiation and promotion stages of proto oncogenes. Photochem photobio.1992;156: 195 – 199.

Damen J, Ramshorst JR, Hoeven RPV and Blitterswijk WJV. Alterations in plasma lipoproteins and heparin releasable lipase activities in mice bearing the GRSC ascites tumor. Biochem. Biophys. Acta. 1984 ;793: 287-296.

Dessi S, Batetta B, Anchisi C, Pani P, Costelli P, Tessitore L and Baccino FM. Cholesterol metabolism during the growth of a rat ascites hepatoma (yoshida AH-130). Br.J.Cancer. 1992; 66:787-793.

Diatlovitskaia EV. and Bergelson LD. Tumor lipids and their effect on the structure and function of cell membranes. Vestn. Akad. Med. Nauk. SSR. 1982; 3:42-47.

Helmes MH, Modia A, Moneim EL, Moustafae MS, Bale EL and Safinoz MEL. (1998). Clinical values of serum LDH, ceruloplasmin and lipid bound sialic acid in monitoring patients with malignant lymphomas. Medical Science Research, 26: 613-617. Henderson BE, Ross RK, Pike M. Toward the primary prevention of cancer. Science. 1991; 254: 1131 - 38.

Hron WT. and Menahan LA. A sensitive method for the determination of free fatty acids in plasma. J. Lipid Res. 1981; 23: 377-381.

Hunter, DJ, Spiegelman D, Advani H, Beesun L, vanden brandt A. Studies of fat intake and the risk of breast cancer a pooled analysis.N. Engl. J. med 1996; 334: 356 - 361.

Kolanjiappan K, Manoharan S. and Kayalvizhi M. Measurement of erythrocyte lipids, lipid peroxidation antioxidants and osmotic fragility in cervical Cancer patients. Clin. Chimica Acta.2002. 326: 143 – 149.

Leffler HH. and Mc Dougald CH. Estimation of cholesterol in serum. Am.J. Clin. Patho1963; 39: 311-313.

Legraud A, Guillanssear RJ. and Land J. Method colorimetric simple determination del activity, de la lecithin cholesterol acyl transferase (LCAT), plasma tiqre interest on diabetodogic. In: Bidrgic prospectives.Sies G and Glatean MM (Eds). Poris, Masson. 1979; 368-371.

Parekh AL and Jung DH. Cholesterol determination with ferric choride-uranyl acetate and sulphuric acid ferrous sulphate reagent. Anal. Biochem. 1970; 42: 1423-1427.

Potischman N, Culloch MC, Byers CE, Houghton T, Nemoto L, Graham T. and Campbell TC. Associations between breast cancer, plasma triglycerides and cholesterol. Nutr. Cancer. 1991; 15(3-4): 205-215.

Rao KN, Kottapally S, Eskander Ed, Shinozuka H, Dessi S. and Pani P. Acinar cell carcinoma of rat pancreas: regulation of cholesterol esterification. Br.J.Cancer. 1986; 54:305-310.

Ray R, Sharma BK, Bahadur AK, Pasha ST, Bhadola P. and Murthy NS. Serum lipid profile and its relationship with host immunity in carcinomas of the breast and uterine cervix. Tumor. 1997; 83(6): 943-94.

Rice EW. 1970 Triglycerides in serum. In: Standard methods of clinical chemistry. Academic press, NY.1981; 6:213-222.

Rogers MP. and Hutchinson I. The effect of invitro high density lipoprotein on hydrolysis of triacyl glycerol by lipoprotein lipase. Biochem. 1981; J 200:453-457.

Schmidt A. Measurement of lipoprotein lipase and hepatic triglyceride lipase in human post heparin plasma. Meth. Enzymol.1974; 72: 325-327.

Stavric B. and Matula TI. Flavanoids in foods. Their significance for nutrition and health. In : Lipid soluble antioxidants biochemistry and clinical applications. Org. A.S.H. and Parker, L. (eds). Brikhauser verlag, Basel, Switzerland. 1992; 274-293.

Thirunavukkarasu C, Selvendiran K, Prince Vijeyasingh J, Senthilnathan P. and Sakthisekaran D. Effect of sodium selenite on lipids and lipid metabolizing enzymes in Nnitrosodiethylamine – Induced hepatoma – bearing rats. The journal of trace elements in experimental Medicine. 2003; 16: 1-15.